Press Release

Daewoong Pharmaceutical’s press release

NEW 1 Daewoong Pharmaceutical's AI System Processes 800 Million Compounds, Boosting Obesity and Cancer Research: 2024-0221

NEW 2 Daewoong Pharmaceutical Announces 2023 Financial Results: 2024-0205

NEW 3 Daewoong Pharmaceutical's Bersiporocin Receives ‘Orphan Drug Designation’ in Europe to Treat Idiopathic Pulmonary Fibrosis: 2024-0129

Daewoong Pharmaceutical's AI System Processes 800 Million Compounds, Boosting Obesity and Cancer Research 2024-02-21
Daewoong Pharmaceutical Announces 2023 Financial Results 2024-02-05
Daewoong Pharmaceutical's Bersiporocin Receives ‘Orphan Drug Designation’ in Europe to Treat Idiopathic Pulmonary Fibrosis 2024-01-29
Daewoong Pharmaceutical and Zydus Announce Exclusive Licensing Agreement for Development and Commercialization of Leuprolide Long-Acting Injectable in the U.S. 2023-12-11
Daewoong Pharmaceutical Strikes a $60 Million Deal with JSC Pharmasyntez for Diabetes Novel Drug Enavogliflozin 2023-12-06
Daewoong Pharmaceutical Received GMP Certification from Brazilian ANVISA 2023-11-28
Daewoong Pharmaceutical to Initiate Clinical Trials Early Next Year for Innovative 'GLP-1 Obesity Treatment' with Advanced Microneedle Technology for Sustained Weekly Efficacy 2023-11-07
Daewoong Pharmaceutical Reports Third Quarter 2023 Financial Results 2023-11-06
Daewoong Pharmaceutical announces ‘3E Global Hyper-Competitive Strategy' at CPHI 2023... Aiming for USD 745M in novel drug sales by 2030 2023-10-26

1 2 3 4 5 6 7 8 9 10 다음 페이지

Search